Staidson Beijing Biopharma (300204) — Capital Reinvestment Ratio

Latest as of March 2020: 1.01x

Staidson Beijing Biopharma (300204) has a Capital Reinvestment Ratio of 1.01x as of March 2020, meaning it reinvests 1% of its operating cash flow (CN¥26.92 Million) in capital expenditures (CN¥27.14 Million). See 300204 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

1.01x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥26.92 Million
CNY

Capital Expenditures

CN¥27.14 Million
CNY

Data as of

Mar 2020
Most recent filing

Staidson Beijing Biopharma Capital Reinvestment Ratio (2007–2019)

This chart tracks Staidson Beijing Biopharma's Capital Reinvestment Ratio across 13 annual periods.

Annual Capital Reinvestment Ratio for Staidson Beijing Biopharma (2007–2019)

Year-by-year Capital Reinvestment Ratio for Staidson Beijing Biopharma from 2007 to 2019. For live market cap and broader valuation context, see market cap of Staidson Beijing Biopharma.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2019 1.35x CN¥44.34 Million CN¥59.91 Million ▲ +133.6%
2018 0.58x CN¥165.08 Million CN¥95.46 Million ▲ +239.9%
2017 0.17x CN¥273.64 Million CN¥46.55 Million ▲ +36.7%
2016 0.12x CN¥212.55 Million CN¥26.45 Million ▲ +20.0%
2015 0.10x CN¥231.01 Million CN¥23.95 Million ▲ +48.2%
2014 0.07x CN¥206.85 Million CN¥14.47 Million ▼ -66.2%
2013 0.21x CN¥111.36 Million CN¥23.02 Million ▼ -68.3%
2012 0.65x CN¥90.19 Million CN¥58.88 Million ▼ -32.7%
2011 0.97x CN¥87.01 Million CN¥84.35 Million ▼ -24.7%
2010 1.29x CN¥63.91 Million CN¥82.25 Million ▲ +313.3%
2009 0.31x CN¥42.37 Million CN¥13.19 Million ▼ -69.9%
2008 1.04x CN¥16.23 Million CN¥16.81 Million ▲ +1535.6%
2007 0.06x CN¥5.41 Million CN¥342.40K —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow